Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Eyevensys Announces an Equity Investment by Boehringer Ingelheim Venture Fund

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, joins Eyevensys’ board of directors.

Eyevensys, a developer of a new process for non-viral gene therapy using electrotransfer that enables prolonged production of therapeutic proteins for the treatment of ocular disease, today announces an equity investment by the Boehringer Ingelheim Venture Fund (BIVF). It also announces that Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, has been appointed to its board of directors.

This equity investment by BIVF marks the start of Eyevensys' next round of funding, which is planned to take place before the end of the second quarter of 2013 and aims to fund the business through to completion of Phase IIa clinical trials. The Eyevensys investment is BIVF's sixth since its launch in 2010 and its first investment in a French company. BIVF had previously taken a stake in Inserm Transfert Initiative, an investment company specializing in seed capital for start-ups coming out of academic research and a past investor in Eyevensys.

The company's past investors (Innobio, managed by CDC Entreprises, Inserm Transfert Initiative and CapDecisif Management) also intend to participate in this second round of funding. Eyevensys raised EUR 1.6 million from its first round of funding in January 2012.

“Boehringer Ingelheim Venture Fund's equity investment brings us credibility, further raises our profile and gives us access to their wealth of experience in pharmaceutical and biotechnology R&D. This sends a strong signal to our target market,” said Dr Ivan Cohen-Tanugi, chairman of Eyevensys. “Dr Michel Pairet is well known in our industry. His experience, combined with the experience of the BIVF team, will undoubtedly help us to strengthen our development. We plan to complete a new round of funding between now and June. Discussions are already underway with potential new investors.”

The aim of this second round is to allow the company to finalize its preclinical trials, proceed to clinical trials within 18 months and complete Phase IIa. Eyevensys is currently focusing on two ophthalmological indications with significant unmet medical needs. These are: uveitis, a rare disease, and age-related macular degeneration, a pathology which occurs more frequently than uveitis and is becoming more prevalent as a result of population aging.

Eyevensys is the only company to have reached this advanced stage of investigation of novel treatment approaches for non-viral gene therapy. The technology developed by Eyevensys involves the electrotransfer of plasmids into the ciliary muscle resulting in a stable, sustained expression of therapeutic proteins. This new therapeutic approach will be less invasive than current therapies, as the frequency of injections can be greatly reduced from fortnightly or monthly to every six months potentially improving the quality of life of patients. Alongside higher efficacy it is hoped that the reduced doses of medication and proteins could also reduce side-effects. The first preclinical results in animal models have shown the expression of therapeutic proteins for up to nine months.

“Eyevensys' novel approach, which targets pathologies where few therapies are available and offers potential advantages in terms of effectiveness, administration and tolerability, makes it a perfect fit with the Boehringer Ingelheim fund's criteria for investment,” explains Dr Michel Pairet, head of non-clinical research and development at Boehringer Ingelheim. “In the future, medicine will increasingly rely on a combination of technologies, as we see here with the combination of gene therapy with a medical device.”

Michel Pairet has been with Boehringer Ingelheim since 1992. Before heading up the German company’s worldwide non-clinical research and development division, he was responsible for its worldwide research, and its corporate investment fund. Michel Pairet is a doctor of veterinary medicine and has a PhD in physiology and pharmacology.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Eyevensys Appoints Dr Ivan Cohen-Tanugi as CEO
Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.
Tuesday, March 26, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!